KR102138241B1 - Composition for the preventing loss of hair and promoting growth of hair comprising rotenone as an active ingredient - Google Patents
Composition for the preventing loss of hair and promoting growth of hair comprising rotenone as an active ingredient Download PDFInfo
- Publication number
- KR102138241B1 KR102138241B1 KR1020190022918A KR20190022918A KR102138241B1 KR 102138241 B1 KR102138241 B1 KR 102138241B1 KR 1020190022918 A KR1020190022918 A KR 1020190022918A KR 20190022918 A KR20190022918 A KR 20190022918A KR 102138241 B1 KR102138241 B1 KR 102138241B1
- Authority
- KR
- South Korea
- Prior art keywords
- hair
- cells
- rotenone
- promoting
- growth
- Prior art date
Links
- 230000001737 promoting effect Effects 0.000 title claims abstract description 36
- 239000000203 mixture Substances 0.000 title claims abstract description 25
- 239000004480 active ingredient Substances 0.000 title claims abstract description 18
- 229940080817 rotenone Drugs 0.000 title claims description 37
- JUVIOZPCNVVQFO-UHFFFAOYSA-N rotenone Natural products O1C2=C3CC(C(C)=C)OC3=CC=C2C(=O)C2C1COC1=C2C=C(OC)C(OC)=C1 JUVIOZPCNVVQFO-UHFFFAOYSA-N 0.000 title claims description 37
- 201000004384 Alopecia Diseases 0.000 title claims description 11
- 210000004209 hair Anatomy 0.000 title description 44
- 230000012010 growth Effects 0.000 title description 8
- 230000003676 hair loss Effects 0.000 title description 8
- 230000003779 hair growth Effects 0.000 claims abstract description 56
- 230000001965 increasing effect Effects 0.000 claims abstract description 30
- 230000035755 proliferation Effects 0.000 claims abstract description 25
- 230000003658 preventing hair loss Effects 0.000 claims abstract description 18
- 239000002537 cosmetic Substances 0.000 claims abstract description 11
- 210000000481 breast Anatomy 0.000 claims abstract description 10
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract description 9
- 208000024963 hair loss Diseases 0.000 claims description 8
- 239000006071 cream Substances 0.000 claims description 5
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000000843 powder Substances 0.000 claims description 4
- 230000003752 improving hair Effects 0.000 claims description 3
- 239000006210 lotion Substances 0.000 claims description 3
- 239000000243 solution Substances 0.000 claims description 3
- 239000007921 spray Substances 0.000 claims description 3
- 238000009472 formulation Methods 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000000344 soap Substances 0.000 claims description 2
- 239000004094 surface-active agent Substances 0.000 claims description 2
- 239000000725 suspension Substances 0.000 claims description 2
- 230000003784 hair-inductive capacity Effects 0.000 claims 2
- 239000003921 oil Substances 0.000 claims 1
- 230000000694 effects Effects 0.000 abstract description 41
- 150000003254 radicals Chemical class 0.000 abstract description 29
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 abstract description 27
- 229910052760 oxygen Inorganic materials 0.000 abstract description 27
- 239000001301 oxygen Substances 0.000 abstract description 27
- 238000013508 migration Methods 0.000 abstract description 13
- 230000005012 migration Effects 0.000 abstract description 12
- 238000001727 in vivo Methods 0.000 abstract description 10
- 238000000338 in vitro Methods 0.000 abstract description 4
- 210000004027 cell Anatomy 0.000 description 115
- 230000002500 effect on skin Effects 0.000 description 43
- 229930182536 Antimycin Natural products 0.000 description 27
- CQIUKKVOEOPUDV-IYSWYEEDSA-N antimycin Chemical compound OC1=C(C(O)=O)C(=O)C(C)=C2[C@H](C)[C@@H](C)OC=C21 CQIUKKVOEOPUDV-IYSWYEEDSA-N 0.000 description 26
- 238000012258 culturing Methods 0.000 description 13
- 239000003642 reactive oxygen metabolite Substances 0.000 description 13
- 230000012292 cell migration Effects 0.000 description 12
- 241000700159 Rattus Species 0.000 description 11
- 230000004663 cell proliferation Effects 0.000 description 10
- 239000001963 growth medium Substances 0.000 description 10
- 238000000034 method Methods 0.000 description 10
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 9
- 238000012790 confirmation Methods 0.000 description 9
- 210000003780 hair follicle Anatomy 0.000 description 9
- 210000003491 skin Anatomy 0.000 description 9
- 238000002965 ELISA Methods 0.000 description 8
- 238000010171 animal model Methods 0.000 description 8
- 239000002609 medium Substances 0.000 description 8
- 239000013028 medium composition Substances 0.000 description 8
- 230000010261 cell growth Effects 0.000 description 7
- 239000006228 supernatant Substances 0.000 description 7
- CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 6
- 230000003698 anagen phase Effects 0.000 description 6
- 230000003660 hair regeneration Effects 0.000 description 6
- 238000011534 incubation Methods 0.000 description 6
- GOCUAJYOYBLQRH-UHFFFAOYSA-N 2-(4-{[3-chloro-5-(trifluoromethyl)pyridin-2-yl]oxy}phenoxy)propanoic acid Chemical compound C1=CC(OC(C)C(O)=O)=CC=C1OC1=NC=C(C(F)(F)F)C=C1Cl GOCUAJYOYBLQRH-UHFFFAOYSA-N 0.000 description 5
- 239000005630 Diquat Substances 0.000 description 5
- 238000002835 absorbance Methods 0.000 description 5
- 230000003115 biocidal effect Effects 0.000 description 5
- SYJFEGQWDCRVNX-UHFFFAOYSA-N diquat Chemical compound C1=CC=[N+]2CC[N+]3=CC=CC=C3C2=C1 SYJFEGQWDCRVNX-UHFFFAOYSA-N 0.000 description 5
- 230000002708 enhancing effect Effects 0.000 description 5
- 230000006698 induction Effects 0.000 description 5
- 239000000126 substance Substances 0.000 description 5
- 229930182566 Gentamicin Natural products 0.000 description 4
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 4
- 241000699670 Mus sp. Species 0.000 description 4
- 150000001875 compounds Chemical class 0.000 description 4
- 229960002518 gentamicin Drugs 0.000 description 4
- -1 lepivacaine Chemical compound 0.000 description 4
- 238000012545 processing Methods 0.000 description 4
- 102000004142 Trypsin Human genes 0.000 description 3
- 108090000631 Trypsin Proteins 0.000 description 3
- 239000001569 carbon dioxide Substances 0.000 description 3
- 229910002092 carbon dioxide Inorganic materials 0.000 description 3
- 239000003795 chemical substances by application Substances 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- CEAZRRDELHUEMR-UHFFFAOYSA-N gentamicin Chemical compound O1C(C(C)NC)CCC(N)C1OC1C(O)C(OC2C(C(NC)C(C)(O)CO2)O)C(N)CC1N CEAZRRDELHUEMR-UHFFFAOYSA-N 0.000 description 3
- 230000001976 improved effect Effects 0.000 description 3
- 230000001939 inductive effect Effects 0.000 description 3
- 238000005259 measurement Methods 0.000 description 3
- 230000002062 proliferating effect Effects 0.000 description 3
- 239000012588 trypsin Substances 0.000 description 3
- 238000005303 weighing Methods 0.000 description 3
- 102400000888 Cholecystokinin-8 Human genes 0.000 description 2
- 101800005151 Cholecystokinin-8 Proteins 0.000 description 2
- AOJJSUZBOXZQNB-TZSSRYMLSA-N Doxorubicin Chemical compound O([C@H]1C[C@@](O)(CC=2C(O)=C3C(=O)C=4C=CC=C(C=4C(=O)C3=C(O)C=21)OC)C(=O)CO)[C@H]1C[C@H](N)[C@H](O)[C@H](C)O1 AOJJSUZBOXZQNB-TZSSRYMLSA-N 0.000 description 2
- ZFMITUMMTDLWHR-UHFFFAOYSA-N Minoxidil Chemical compound NC1=[N+]([O-])C(N)=CC(N2CCCCC2)=N1 ZFMITUMMTDLWHR-UHFFFAOYSA-N 0.000 description 2
- 108010081996 Photosystem I Protein Complex Proteins 0.000 description 2
- GLNADSQYFUSGOU-GPTZEZBUSA-J Trypan blue Chemical compound [Na+].[Na+].[Na+].[Na+].C1=C(S([O-])(=O)=O)C=C2C=C(S([O-])(=O)=O)C(/N=N/C3=CC=C(C=C3C)C=3C=C(C(=CC=3)\N=N\C=3C(=CC4=CC(=CC(N)=C4C=3O)S([O-])(=O)=O)S([O-])(=O)=O)C)=C(O)C2=C1N GLNADSQYFUSGOU-GPTZEZBUSA-J 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 231100000360 alopecia Toxicity 0.000 description 2
- BLFLLBZGZJTVJG-UHFFFAOYSA-N benzocaine Chemical compound CCOC(=O)C1=CC=C(N)C=C1 BLFLLBZGZJTVJG-UHFFFAOYSA-N 0.000 description 2
- 230000030833 cell death Effects 0.000 description 2
- 230000032823 cell division Effects 0.000 description 2
- 238000005119 centrifugation Methods 0.000 description 2
- 239000003153 chemical reaction reagent Substances 0.000 description 2
- ZPUCINDJVBIVPJ-LJISPDSOSA-N cocaine Chemical compound O([C@H]1C[C@@H]2CC[C@@H](N2C)[C@H]1C(=O)OC)C(=O)C1=CC=CC=C1 ZPUCINDJVBIVPJ-LJISPDSOSA-N 0.000 description 2
- 231100000135 cytotoxicity Toxicity 0.000 description 2
- 230000003013 cytotoxicity Effects 0.000 description 2
- 230000003412 degenerative effect Effects 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 201000010099 disease Diseases 0.000 description 2
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 230000006870 function Effects 0.000 description 2
- 239000003102 growth factor Substances 0.000 description 2
- 210000000442 hair follicle cell Anatomy 0.000 description 2
- 229940088597 hormone Drugs 0.000 description 2
- 239000005556 hormone Substances 0.000 description 2
- 239000004615 ingredient Substances 0.000 description 2
- 230000003993 interaction Effects 0.000 description 2
- KQPYUDDGWXQXHS-UHFFFAOYSA-N juglone Chemical compound O=C1C=CC(=O)C2=C1C=CC=C2O KQPYUDDGWXQXHS-UHFFFAOYSA-N 0.000 description 2
- 230000007246 mechanism Effects 0.000 description 2
- PQLXHQMOHUQAKB-UHFFFAOYSA-N miltefosine Chemical compound CCCCCCCCCCCCCCCCOP([O-])(=O)OCC[N+](C)(C)C PQLXHQMOHUQAKB-UHFFFAOYSA-N 0.000 description 2
- 229960003632 minoxidil Drugs 0.000 description 2
- 210000003470 mitochondria Anatomy 0.000 description 2
- VCMMXZQDRFWYSE-UHFFFAOYSA-N plumbagin Chemical compound C1=CC=C2C(=O)C(C)=CC(=O)C2=C1O VCMMXZQDRFWYSE-UHFFFAOYSA-N 0.000 description 2
- 230000008569 process Effects 0.000 description 2
- 230000027756 respiratory electron transport chain Effects 0.000 description 2
- 230000000284 resting effect Effects 0.000 description 2
- 150000003839 salts Chemical class 0.000 description 2
- IZTQOLKUZKXIRV-YRVFCXMDSA-N sincalide Chemical compound C([C@@H](C(=O)N[C@@H](CCSC)C(=O)NCC(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC=1C=CC=CC=1)C(N)=O)NC(=O)[C@@H](N)CC(O)=O)C1=CC=C(OS(O)(=O)=O)C=C1 IZTQOLKUZKXIRV-YRVFCXMDSA-N 0.000 description 2
- 230000036560 skin regeneration Effects 0.000 description 2
- 238000010186 staining Methods 0.000 description 2
- UCSJYZPVAKXKNQ-HZYVHMACSA-N streptomycin Chemical compound CN[C@H]1[C@H](O)[C@@H](O)[C@H](CO)O[C@H]1O[C@@H]1[C@](C=O)(O)[C@H](C)O[C@H]1O[C@@H]1[C@@H](NC(N)=N)[C@H](O)[C@@H](NC(N)=N)[C@H](O)[C@H]1O UCSJYZPVAKXKNQ-HZYVHMACSA-N 0.000 description 2
- LEBVLXFERQHONN-UHFFFAOYSA-N 1-butyl-N-(2,6-dimethylphenyl)piperidine-2-carboxamide Chemical compound CCCCN1CCCCC1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-UHFFFAOYSA-N 0.000 description 1
- 230000002407 ATP formation Effects 0.000 description 1
- 102000000452 Acetyl-CoA carboxylase Human genes 0.000 description 1
- 108010016219 Acetyl-CoA carboxylase Proteins 0.000 description 1
- 108010018763 Biotin carboxylase Proteins 0.000 description 1
- 102100025287 Cytochrome b Human genes 0.000 description 1
- 102000019265 Cytochrome c1 Human genes 0.000 description 1
- 108010075028 Cytochromes b Proteins 0.000 description 1
- 108010007528 Cytochromes c1 Proteins 0.000 description 1
- 102000004127 Cytokines Human genes 0.000 description 1
- 108090000695 Cytokines Proteins 0.000 description 1
- 244000147058 Derris elliptica Species 0.000 description 1
- 241000790917 Dioxys <bee> Species 0.000 description 1
- 229940124602 FDA-approved drug Drugs 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 description 1
- ZMOIGGHUSNHCAB-UHFFFAOYSA-N Isoplumbagin Natural products C1=CC(O)=C2C(=O)C(C)=CC(=O)C2=C1 ZMOIGGHUSNHCAB-UHFFFAOYSA-N 0.000 description 1
- NNJVILVZKWQKPM-UHFFFAOYSA-N Lidocaine Chemical compound CCN(CC)CC(=O)NC1=C(C)C=CC=C1C NNJVILVZKWQKPM-UHFFFAOYSA-N 0.000 description 1
- 229930193140 Neomycin Natural products 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- UOZODPSAJZTQNH-UHFFFAOYSA-N Paromomycin II Natural products NC1C(O)C(O)C(CN)OC1OC1C(O)C(OC2C(C(N)CC(N)C2O)OC2C(C(O)C(O)C(CO)O2)N)OC1CO UOZODPSAJZTQNH-UHFFFAOYSA-N 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- 230000032683 aging Effects 0.000 description 1
- 239000003242 anti bacterial agent Substances 0.000 description 1
- 230000000843 anti-fungal effect Effects 0.000 description 1
- 229940088710 antibiotic agent Drugs 0.000 description 1
- 229940121375 antifungal agent Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 229960005274 benzocaine Drugs 0.000 description 1
- ALPCEXCHMFUSAN-UHFFFAOYSA-N beta-Dihydroplumbagin Natural products C1=CC=C2C(=O)C(C)CC(=O)C2=C1O ALPCEXCHMFUSAN-UHFFFAOYSA-N 0.000 description 1
- VYTBDSUNRJYVHL-UHFFFAOYSA-N beta-Hydrojuglone Natural products O=C1CCC(=O)C2=C1C=CC=C2O VYTBDSUNRJYVHL-UHFFFAOYSA-N 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 229960003150 bupivacaine Drugs 0.000 description 1
- 239000006227 byproduct Substances 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 239000000969 carrier Substances 0.000 description 1
- 239000006143 cell culture medium Substances 0.000 description 1
- 230000003915 cell function Effects 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 230000009087 cell motility Effects 0.000 description 1
- 230000005754 cellular signaling Effects 0.000 description 1
- 229960001747 cinchocaine Drugs 0.000 description 1
- PUFQVTATUTYEAL-UHFFFAOYSA-N cinchocaine Chemical compound C1=CC=CC2=NC(OCCCC)=CC(C(=O)NCCN(CC)CC)=C21 PUFQVTATUTYEAL-UHFFFAOYSA-N 0.000 description 1
- 238000004140 cleaning Methods 0.000 description 1
- 229960003920 cocaine Drugs 0.000 description 1
- 238000007796 conventional method Methods 0.000 description 1
- 230000034994 death Effects 0.000 description 1
- 230000003247 decreasing effect Effects 0.000 description 1
- 206010012601 diabetes mellitus Diseases 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229960004679 doxorubicin Drugs 0.000 description 1
- 210000001339 epidermal cell Anatomy 0.000 description 1
- 210000002919 epithelial cell Anatomy 0.000 description 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 description 1
- 229960004039 finasteride Drugs 0.000 description 1
- DBEPLOCGEIEOCV-WSBQPABSSA-N finasteride Chemical compound N([C@@H]1CC2)C(=O)C=C[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H](C(=O)NC(C)(C)C)[C@@]2(C)CC1 DBEPLOCGEIEOCV-WSBQPABSSA-N 0.000 description 1
- 239000003205 fragrance Substances 0.000 description 1
- 239000003966 growth inhibitor Substances 0.000 description 1
- 239000003630 growth substance Substances 0.000 description 1
- 230000031774 hair cycle Effects 0.000 description 1
- 230000009583 hair follicle growth Effects 0.000 description 1
- 150000004677 hydrates Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 239000001257 hydrogen Substances 0.000 description 1
- 210000000987 immune system Anatomy 0.000 description 1
- 230000036039 immunity Effects 0.000 description 1
- 239000003112 inhibitor Substances 0.000 description 1
- 230000002401 inhibitory effect Effects 0.000 description 1
- 229960000318 kanamycin Drugs 0.000 description 1
- 229930027917 kanamycin Natural products 0.000 description 1
- SBUJHOSQTJFQJX-NOAMYHISSA-N kanamycin Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N SBUJHOSQTJFQJX-NOAMYHISSA-N 0.000 description 1
- 229930182823 kanamycin A Natural products 0.000 description 1
- 230000002147 killing effect Effects 0.000 description 1
- 235000021374 legumes Nutrition 0.000 description 1
- 229960004288 levobupivacaine Drugs 0.000 description 1
- LEBVLXFERQHONN-INIZCTEOSA-N levobupivacaine Chemical compound CCCCN1CCCC[C@H]1C(=O)NC1=C(C)C=CC=C1C LEBVLXFERQHONN-INIZCTEOSA-N 0.000 description 1
- 229960004194 lidocaine Drugs 0.000 description 1
- 150000002632 lipids Chemical class 0.000 description 1
- 230000033001 locomotion Effects 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 210000003866 melanoblast Anatomy 0.000 description 1
- 229960002409 mepivacaine Drugs 0.000 description 1
- INWLQCZOYSRPNW-UHFFFAOYSA-N mepivacaine Chemical compound CN1CCCCC1C(=O)NC1=C(C)C=CC=C1C INWLQCZOYSRPNW-UHFFFAOYSA-N 0.000 description 1
- 230000002438 mitochondrial effect Effects 0.000 description 1
- 230000008811 mitochondrial respiratory chain Effects 0.000 description 1
- 230000009756 muscle regeneration Effects 0.000 description 1
- 229960004927 neomycin Drugs 0.000 description 1
- 229960000808 netilmicin Drugs 0.000 description 1
- ZBGPYVZLYBDXKO-HILBYHGXSA-N netilmycin Chemical compound O([C@@H]1[C@@H](N)C[C@H]([C@@H]([C@H]1O)O[C@@H]1[C@]([C@H](NC)[C@@H](O)CO1)(C)O)NCC)[C@H]1OC(CN)=CC[C@H]1N ZBGPYVZLYBDXKO-HILBYHGXSA-N 0.000 description 1
- 102000045246 noggin Human genes 0.000 description 1
- 108700007229 noggin Proteins 0.000 description 1
- 235000015097 nutrients Nutrition 0.000 description 1
- 239000002674 ointment Substances 0.000 description 1
- 201000008482 osteoarthritis Diseases 0.000 description 1
- 229960001756 oxaliplatin Drugs 0.000 description 1
- DWAFYCQODLXJNR-BNTLRKBRSA-L oxaliplatin Chemical compound O1C(=O)C(=O)O[Pt]11N[C@@H]2CCCC[C@H]2N1 DWAFYCQODLXJNR-BNTLRKBRSA-L 0.000 description 1
- MMQYUDBFDDEJBP-UHFFFAOYSA-N oxane-3,5-diol Chemical compound OC1COCC(O)C1 MMQYUDBFDDEJBP-UHFFFAOYSA-N 0.000 description 1
- 230000010627 oxidative phosphorylation Effects 0.000 description 1
- 125000004430 oxygen atom Chemical group O* 0.000 description 1
- 208000003154 papilloma Diseases 0.000 description 1
- FIKAKWIAUPDISJ-UHFFFAOYSA-L paraquat dichloride Chemical compound [Cl-].[Cl-].C1=C[N+](C)=CC=C1C1=CC=[N+](C)C=C1 FIKAKWIAUPDISJ-UHFFFAOYSA-L 0.000 description 1
- 229960001914 paromomycin Drugs 0.000 description 1
- UOZODPSAJZTQNH-LSWIJEOBSA-N paromomycin Chemical compound N[C@@H]1[C@@H](O)[C@H](O)[C@H](CN)O[C@@H]1O[C@H]1[C@@H](O)[C@H](O[C@H]2[C@@H]([C@@H](N)C[C@@H](N)[C@@H]2O)O[C@@H]2[C@@H]([C@@H](O)[C@H](O)[C@@H](CO)O2)N)O[C@@H]1CO UOZODPSAJZTQNH-LSWIJEOBSA-N 0.000 description 1
- 235000015927 pasta Nutrition 0.000 description 1
- 230000001575 pathological effect Effects 0.000 description 1
- 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 description 1
- 230000001766 physiological effect Effects 0.000 description 1
- 239000000049 pigment Substances 0.000 description 1
- 238000002360 preparation method Methods 0.000 description 1
- 238000002203 pretreatment Methods 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 102000004169 proteins and genes Human genes 0.000 description 1
- 108090000623 proteins and genes Proteins 0.000 description 1
- PSHUOCODRHYTBQ-UHFFFAOYSA-N pyrazine-1,4-diium;dibromide Chemical compound [Br-].[Br-].C1=C[NH+]=CC=[NH+]1 PSHUOCODRHYTBQ-UHFFFAOYSA-N 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 102000005962 receptors Human genes 0.000 description 1
- 108020003175 receptors Proteins 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000241 respiratory effect Effects 0.000 description 1
- 230000029058 respiratory gaseous exchange Effects 0.000 description 1
- 230000028327 secretion Effects 0.000 description 1
- 230000036299 sexual function Effects 0.000 description 1
- 238000004904 shortening Methods 0.000 description 1
- 230000019491 signal transduction Effects 0.000 description 1
- 239000012453 solvate Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000003381 stabilizer Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 229960005322 streptomycin Drugs 0.000 description 1
- 230000035882 stress Effects 0.000 description 1
- 238000010254 subcutaneous injection Methods 0.000 description 1
- 239000007929 subcutaneous injection Substances 0.000 description 1
- 230000009885 systemic effect Effects 0.000 description 1
- 229960001674 tegafur Drugs 0.000 description 1
- WFWLQNSHRPWKFK-ZCFIWIBFSA-N tegafur Chemical compound O=C1NC(=O)C(F)=CN1[C@@H]1OCCC1 WFWLQNSHRPWKFK-ZCFIWIBFSA-N 0.000 description 1
- 229960002372 tetracaine Drugs 0.000 description 1
- GKCBAIGFKIBETG-UHFFFAOYSA-N tetracaine Chemical compound CCCCNC1=CC=C(C(=O)OCCN(C)C)C=C1 GKCBAIGFKIBETG-UHFFFAOYSA-N 0.000 description 1
- 229960000707 tobramycin Drugs 0.000 description 1
- NLVFBUXFDBBNBW-PBSUHMDJSA-N tobramycin Chemical compound N[C@@H]1C[C@H](O)[C@@H](CN)O[C@@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](N)[C@H](O)[C@@H](CO)O2)O)[C@H](N)C[C@@H]1N NLVFBUXFDBBNBW-PBSUHMDJSA-N 0.000 description 1
- 231100000167 toxic agent Toxicity 0.000 description 1
- 239000003440 toxic substance Substances 0.000 description 1
- 230000001052 transient effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
- 230000035899 viability Effects 0.000 description 1
- 239000011782 vitamin Substances 0.000 description 1
- 235000013343 vitamin Nutrition 0.000 description 1
- 229940088594 vitamin Drugs 0.000 description 1
- 229930003231 vitamin Natural products 0.000 description 1
- 229960004276 zoledronic acid Drugs 0.000 description 1
- XRASPMIURGNCCH-UHFFFAOYSA-N zoledronic acid Chemical compound OP(=O)(O)C(P(O)(O)=O)(O)CN1C=CN=C1 XRASPMIURGNCCH-UHFFFAOYSA-N 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
- A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/365—Lactones
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/14—Drugs for dermatological disorders for baldness or alopecia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q7/00—Preparations for affecting hair growth
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
- C12N5/06—Animal cells or tissues; Human cells or tissues
- C12N5/0602—Vertebrate cells
- C12N5/0625—Epidermal cells, skin cells; Cells of the oral mucosa
- C12N5/0627—Hair cells
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/40—Regulators of development
- C12N2501/48—Regulators of apoptosis
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/70—Enzymes
- C12N2501/71—Oxidoreductases (EC 1.)
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2501/00—Active agents used in cell culture processes, e.g. differentation
- C12N2501/999—Small molecules not provided for elsewhere
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- Epidemiology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Organic Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Wood Science & Technology (AREA)
- General Chemical & Material Sciences (AREA)
- Birds (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Genetics & Genomics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Microbiology (AREA)
- Cell Biology (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Cosmetics (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Abstract
본 발명은 활성산소 공여체(ROS donor)의 새로운 용도에 관한 것으로, 보다 상세하게는 활성산소 공여체를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 약학적 조성물 및 화장료 조성물에 관한 것이다.
본 발명의 활성산소 공여체는 시험관 내에서 모유두 세포의 증식 촉진 및 이주능 증가 효과를 나타내고, 생체 내에서 발모 촉진 효과를 유의적으로 나타낼 수 있으므로, 본 발명의 활성산소 공여체는 탈모 방지 또는 발모 촉진용 조성물의 유효성분으로 유용하게 사용될 수 있다.The present invention relates to a new use of an active oxygen donor (ROS donor), and more particularly, to a pharmaceutical composition and a cosmetic composition for preventing hair loss or promoting hair growth, including an active oxygen donor as an active ingredient.
Since the free radical donor of the present invention exhibits an effect of promoting proliferation of breast papilla cells and increasing migration ability in vitro, and can significantly show a hair growth promoting effect in vivo, the free radical donor of the present invention is used for preventing hair loss or promoting hair growth It can be usefully used as an active ingredient of the composition.
Description
본 발명은 로테논(rotenone)을 포함하는, 탈모 방지 또는 발모 촉진용 조성물에 관한 것이다.The present invention relates to a composition for preventing hair loss or promoting hair growth, comprising rotenone.
모유두 세포(Dermal papilla cell, DPCs)는 모낭 하부의 모유두(dermal papilla)에 위치한 세포로써 모유두 세포에는 모세혈관이 분포하고 있어 이를 통해 모낭에 영양을 공급하고 성장인자(growth factor)와 저해인자(inhibition factor)를 분비하여 모낭 상피세포의 성장을 조절한다. 인체 모발이 성장하기 위해서는 모낭 주위의 여러 인자들의 작용과 모낭 내에 있는 표피 세포와 모유두 세포의 상호작용이 매우 중요하며, 이러한 상호작용에 의해 모발의 성장 및 주기가 조절된다. 활발히 모발이 성장하는 성장기에는 모유두 세포의 활발한 증식 및 분화가 활발하게 일어나며 모발의 성장이 중단되며 탈모현상이 일어나는 퇴행기, 휴지기, 탈모기에는 이 세포가 사멸된다(비특허문헌 1).Dermal papilla cells (DPCs) are cells located in the dermal papilla at the bottom of the hair follicles, and the capillaries are distributed in the dermal papilla cells, thereby supplying nutrients to the hair follicles, thereby providing growth factors and inhibitors. factor) to regulate the growth of hair follicle epithelial cells. In order for human hair to grow, the action of various factors around the hair follicle and the interaction between epidermal cells and dermal papilla cells in the hair follicle are very important, and the growth and cycle of hair are regulated by this interaction. Active growth and differentiation of the papillary cells occurs actively during the growth phase when hair is actively growing, hair growth is stopped, and these cells are killed during the degenerative, resting, and hair loss phases where hair loss occurs (Non-Patent Document 1).
따라서 발모 및 탈모에는 모유두 세포의 증식 및 사멸이 밀접하게 연관되어 있으므로 이의 증식을 유도함으로써 성장기를 길게 하거나 혹은 세포 사멸을 억제하고 퇴행기, 휴지기, 탈모기를 짧게 하는 것이 탈모를 개선, 치료 방안이 될 것으로 주목받고 있다. 또한, 모유두 부근의 세포 분열과 이동은 머리카락의 성장과 밀접한 관련을 갖고 있는데, 성장기에서 모유두로부터 모발이 새롭게 생성되는데, 여러 가지 사이토카인, 호르몬 등에 의해서 세포가 활성화 되어 모유두로 세포의 이동이 나타나 모발의 성장에 영향을 주게 된다(비특허문헌 2, 비특허문헌 3). Therefore, hair growth and alopecia are closely related to proliferation and death of hair papilla cells, so prolonging the growth phase or suppressing cell death and shortening the degenerative phase, resting period, and alopecia will improve and treat hair loss. It is getting attention. In addition, cell division and migration in the vicinity of the papilla are closely related to the growth of hair. In the growth phase, hair is newly generated from the papilla, and cells are activated by various cytokines, hormones, etc., and the movement of the cells to the papilla appears. It affects the growth of (non-patent
현재 발모 및 모발 성장을 촉진할 수 있는 약물로서 FDA에서 승인된 대표적인 약물은 미녹시딜(minoxidil)과 피나스테라이드(finasteride)가 있다. 그러나, 이들 약물은 전신의 발모 및 성기능 저하 등의 부작용이 따르고 미녹시딜의 구체적인 작용 기전 또한 명확하게 밝혀지는 않은 상태이다. 따라서, 모낭에서 모유두 세포의 증식을 촉진하고 성장인자의 발현을 증가시키면서 인체에 안정한 약물을 개발하기 위한 노력을 기울이고 있다.Currently, FDA-approved drugs that can promote hair growth and hair growth include minoxidil and finasteride. However, these drugs have side effects such as systemic hair growth and decreased sexual function, and the specific mechanism of action of minoxidil has not been clearly identified. Therefore, efforts are being made to develop a drug that is stable to the human body while promoting the proliferation of hair papilla cells in the hair follicle and increasing the expression of growth factors.
한편, 약물을 직접 피부에 도포하는 방식 이외에도, 탈모 치료방법으로 모낭 세포를 생체 외에서 배양하여 이식하는 기술이 시도되고 있는데, 모유두 세포를 생체 외에서 분리하여 배양하게 되면 3~4계대 이후에는 모낭유도능력을 점점 상실하게 되는 문제가 있다. 이에, 모유두 세포의 기능을 강화할 수 있는 모유두 세포 활성화 방법의 개발을 위한 노력이 계속되고 있다.On the other hand, in addition to the method of directly applying the drug to the skin, a technique for culturing and transplanting hair follicle cells in vitro as a hair loss treatment method has been attempted. When the papillary cells are separated and cultured in vitro, the ability to induce hair follicles after 3-4 passages There is a problem of getting lost. Accordingly, efforts are being made to develop a method for activating a dermal papilla cell capable of enhancing the function of the papillary cell.
활성산소 또는 활성산소종(reactive oxygen species; ROS)은 산소원자를 포함한, 화학적으로 반응성 있는 분자로서, 성인병과 암을 비롯한 질병 또는 노화를 일으키는 원인이기도 하지만, 반대로 면역체계 강화, 근육 재생, 당뇨병 억제, 퇴행성 관절염을 완화시키는 기능을 하기도 한다. 최근 연구에 의하면 활성산소는 단순히 호흡과정에서 생성되는 부산물이 아니라, 외부자극에 의하여 세포막에 존재하는 수용체를 통하여 일시적으로 생성되는 세포신호전달체계상의 이차신호전달물질(second messenger)로서 작용할 것이라는 연구 결과가 나오고 있다. 즉, 병리적인 상태의 다량의 활성산소는 세포내에서 독성물질로 작용하지만, 외부 신호에 의하여 특정 지역에서 일시적으로 생성되는 낮은 농도의 활성산소는 세포의 성장, 사멸과 더불어 면역 등의 세포 기능을 조절하는 세포 내 이차신호전달물질로 작용할 수도 있다.Free radicals or reactive oxygen species (ROS) are chemically reactive molecules that contain oxygen atoms, which can also cause diseases or aging, including adult diseases and cancer, but, on the contrary, strengthen the immune system, inhibit muscle regeneration, and suppress diabetes Also, it has the function of alleviating degenerative arthritis. According to a recent study, the result of research that free radicals will act as a secondary messenger on the cell signaling system that is temporarily generated through receptors present in the cell membrane by external stimulation, not by-products generated during the breathing process. Is coming out. In other words, a large amount of free radicals in a pathological state acts as a toxic substance in the cell, but low concentrations of free radicals temporarily generated in a specific region by external signals are responsible for cell functions such as immunity as well as cell growth and death. It can also act as a secondary signal transduction agent in the cells that regulate.
한편, 활성산소 공여체 중 로테논(Rotenone)과 안티마이신(Antimycin)은 미토콘드리아에서 ATP 합성이 일어나지 않도록 산화적 인산화를 억제하며, 특히 로테논은 10-100 nM의 농도에서 세포 성장과 분열을 억제하는 것으로 알려져 있다. 그러나, 로테논과 안티마이신을 포함하는 활성산소 공여체의 발모 효과에 대해서는 아직까지 확인된 바가 없다.On the other hand, of the free radical donors, Rotenone and Antimycin inhibit oxidative phosphorylation so that ATP synthesis does not occur in mitochondria, and especially Rotenone inhibits cell growth and division at a concentration of 10-100 nM. It is known. However, the hair growth effect of an active oxygen donor containing rotenone and antimycin has not been confirmed.
이러한 배경 하에, 본 발명자들은 모유두 세포에 활성산소 공여체를 처리하면 모유두 세포의 증식능 및 이주능이 촉진되고, 실험동물에 활성산소 공여체 처리 시 발모 촉진 효과가 현저하게 향상된 것을 확인하였다. 나아가, 활성산소 공여체로 전 처리된 모유두 세포의 발모능 강화 효과를 확인하여 본 발명을 완성하였다.Under these backgrounds, the present inventors have confirmed that treatment of the free radical donor to the papillary cells promotes the proliferation and migration ability of the papillary cells, and significantly improves the hair growth promoting effect when the free radical donor is treated with the experimental animal. Furthermore, the present invention was completed by confirming the effect of enhancing hair growth capacity of the papillary cells pre-treated with an active oxygen donor.
따라서, 본 발명의 목적은 시험관 내(in vitro) 및 생체 내(in vivo)에서 모유두 세포의 증식 촉진, 이동능 증가, 수명 증가 및 발모능을 강화시킬 수 있는 조성물을 제공하는 데 있다.Accordingly, it is an object of the present invention to provide a composition capable of enhancing proliferation of breast papilla cells, increasing mobility, increasing lifespan, and enhancing hair growth in vitro and in vivo.
본 발명의 다른 목적은 발모능이 강화된 모유두 세포 또는 그 배양액을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 조성물을 제공하는 데 있다.Another object of the present invention is to provide a composition for preventing hair loss or promoting hair growth, comprising hair papilla cells having enhanced hair growth ability or a culture medium thereof as an active ingredient.
본 발명의 또 다른 목적은 모유두 세포의 증식 촉진, 이동능 증가, 수명 증가 및 발모능을 강화시킬 수 있는, 모유두 세포의 증식방법 및 배지 조성물을 제공하는 데 있다.Another object of the present invention is to provide a method and media composition for proliferation of papillary cells, capable of promoting proliferation of breast papilla cells, increasing mobility, increasing lifespan and enhancing hair growth capacity.
상기 과제를 해결하기 위하여, 본 발명은 활성산소 공여체(ROS donor)를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 약학적 조성물을 제공한다.In order to solve the above problems, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth, which includes an active oxygen donor (ROS donor) as an active ingredient.
본 발명은 또한, 활성산소 공여체(ROS donor)를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 화장료 조성물을 제공한다.The present invention also provides a cosmetic composition for preventing hair loss or promoting hair growth comprising an active oxygen donor (ROS donor) as an active ingredient.
본 발명은 또한, 활성산소 공여체(ROS donor)가 포함된 배지에서 배양된 모유두 세포를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 약학적 조성물을 제공한다.The present invention also provides a pharmaceutical composition for preventing hair loss or promoting hair growth, which includes hair papilla cells cultured in a medium containing an active oxygen donor (ROS donor) as an active ingredient.
본 발명은 또한, 활성산소 공여체(ROS donor)가 포함된 배지에서 모유두 세포를 배양하는 단계를 포함하는 모유두 세포의 증식방법을 제공한다.The present invention also provides a method for proliferating a dermal papilla cell comprising culturing the dermal papilla cell in a medium containing an active oxygen donor (ROS donor).
본 발명은 또한, 활성산소 공여체(ROS donor)를 유효성분으로 포함하는 모유두 세포 배양용 배지 조성물을 제공한다.The present invention also provides a media composition for culturing a papillary cell comprising an active oxygen donor (ROS donor) as an active ingredient.
본 발명에 따른 활성산소 공여체(ROS donor)는 모유두 세포의 증식을 촉진하고 세포 이주능 증가 효과를 나타내며, 털을 제거한 마우스 등에서 발모 촉진 효과를 유의적으로 나타낼 수 있으므로, 탈모 방지 또는 발모 촉진용 약학적 조성물, 화장료 조성물의 유효성분으로 유용하게 사용될 수 있다.The free radical donor (ROS donor) according to the present invention promotes the proliferation of breast papilla cells and shows the effect of increasing cell migration ability, and can significantly exhibit the effect of promoting hair growth in mice with hair removed, etc., thus preventing or preventing hair loss. It can be usefully used as an active ingredient in red compositions and cosmetic compositions.
또한, 본 발명에 따른 활성산소 공여체(ROS donor)를 모유두 세포 배양 배지에 첨가하여 모유두 세포를 배양하였을 때, 모유두 세포의 증식을 촉진하고, 세포 이주능 증가 효과를 나타내며, 활성산소 공여체를 처리하여 배양된 모유두 세포는 활성산소 공여체를 처리하지 않고 배양된 모유두 세포 대비 모낭유도능력이 월등하게 향상된 우수한 효과가 있으므로, 본 발명의 활성산소 공여체로 전 처리된 모유두 세포를 탈모 치료제로 유용하게 사용될 수 있다.In addition, when the papillary cells are cultured by adding the free radical donor (ROS donor) according to the present invention to the papillary cell culture medium, it promotes the proliferation of the papillary cells, shows the effect of increasing cell migration ability, and treats the free radical donor. Since the cultured dermal papilla cells have an excellent effect that the hair follicle inducing ability is significantly improved compared to the cultured dermal papilla cells without treating the reactive oxygen donor, the dermal papilla cells pre-treated with the active oxygen donor of the present invention can be usefully used as a hair loss treatment agent. .
도 1은 활성산소 공여체의 처리가 모유두 세포의 증식에 미치는 효과를 확인한 결과이다:
도 1a는 모유두 세포에 로테논(rotenone)을 농도별로 처리 및 배양한 후 ELISA 리더기로 흡광도를 측정하여 세포 증식 정도를 확인한 결과;
도 1b는 모유두 세포에 안티마이신(antymicin)을 농도 별로 처리 및 배양한 후 ELISA 리더기로 흡광도를 측정하여 세포 증식 정도를 확인한 결과;
도 1c는 모유두 세포에 할록시포프(haloxyfop)를 농도 별로 처리 및 배양한 후 ELISA 리더기로 흡광도를 측정하여 세포 증식 정도를 확인한 결과;
도 1d는 모유두 세포에 다이쿼드(diquat)를 농도 별로 처리 및 배양한 후 ELISA 리더기로 흡광도를 측정하여 세포 증식 정도를 확인한 결과;
도 1e는 모유두 세포에 젠타마이신(gentamicine)을 농도 별로 처리 및 배양한 후 ELISA 리더기로 흡광도를 측정하여 세포 증식 정도를 확인한 결과.
도 2는 활성산소 공여체의 처리가 모유두 세포의 이동에 미치는 효과를 확인한 결과이다:
도 2a는 모유두 세포에 로테논을 농도 별로 처리 및 배양한 후 세포 이동능력을 확인한 결과를 나타낸 것;
도 2b는 모유두 세포에 안티마이신을 농도 별로 처리 및 배양한 후 세포 이동능력을 확인한 결과를 나타낸 것.
도 3은 생체 내에서 활성산소 공여체의 처리가 발모에 미치는 효과를 확인한 결과이다:
도 3a는 실험동물의 등 부위의 털을 제거한 후 로테논을 농도별로 14일 동안 발라준 후 새로 자란 털의 무게측정을 통해 발모 효과를 확인한 결과를 나타낸 것;
도 3b는 실험동물의 등 부위의 털을 제거한 후 안티마이신을 농도 별로 14일 동안 발라준 후 새로 자란 털의 무게측정을 통해 발모 효과를 확인한 것.
도 4는 생체 내에서 활성산소 공여체로 전 처리된 모유두 세포가 발모에 미치는 효과를 확인한 결과이다:
도 4a는 실험동물에 로테논으로 전 처리된 모유두 세포를 피하주사하고 14일 후 새로 자란 털의 무게를 측정하여 발모 효과를 확인한 결과;
도 4b는 실험동물에 안티마이신으로 전 처리된 모유두 세포를 피하주사하고 14일 후 새로 자란 털의 무게를 측정하여 발모 효과를 결과.1 is a result confirming the effect of treatment of free radical donors on the proliferation of dermal papilla cells:
Figure 1a is a result of confirming the degree of cell proliferation by measuring the absorbance with an ELISA reader after processing and culturing rotenone by concentration in the dermal papilla cells;
Figure 1b is a result of confirming the degree of cell proliferation by measuring the absorbance with an ELISA reader after treatment and culture of antimycin (antymicin) by concentration in the papillary cells;
Figure 1c is a result of confirming the degree of cell proliferation by measuring the absorbance with ELISA reader after processing and culturing haloxyfop in the papilla cells by concentration;
1D is a result of confirming the degree of cell proliferation by measuring the absorbance with an ELISA reader after treating and culturing diquat on the papilla cells by concentration;
Figure 1e is a result of confirming the degree of cell proliferation by measuring the absorbance with ELISA reader after processing and culturing gentamicin in the papilla cells by concentration.
2 is a result confirming the effect of the treatment of free radical donors on the migration of the dermal papilla cells:
Figure 2a shows the results of confirming the cell migration capacity after processing and culturing the rotenone concentration in the dermal papilla cells;
Figure 2b shows the results of confirming the cell migration ability after treatment and culture by antimycin concentration in the papillary cells.
3 is a result confirming the effect of treatment of free radical donors on hair growth in vivo:
Figure 3a shows the results of confirming the hair growth effect through the weight measurement of newly grown hair after applying the rotenone for 14 days by concentration after removing the hair on the back of the experimental animal;
Figure 3b confirms the hair growth effect by removing the hair on the back of the experimental animal, applying antimycin for 14 days for each concentration, and then weighing the newly grown hair.
4 is a result confirming the effect on the hair growth of the papilloma cells pre-treated with free radical donors in vivo:
Figure 4a is a result of confirming the hair growth effect by subcutaneously injecting papillary cells pre-treated with rotenone into experimental animals and measuring the weight of newly grown hair after 14 days;
Figure 4b shows the hair growth effect by measuring the weight of the newly grown
이하, 본 발명을 상세하게 설명한다.Hereinafter, the present invention will be described in detail.
상술한 바와 같이, 호르몬 분비 변화 외에도 스트레스로 인한 탈모 현상이 증가하면서 탈모 방지 및 모발 성장을 촉진할 수 있는 약학적 조성물 및 화장료 조성물에 대한 요구가 증가하고 있으나, 효과적인 탈모 방지 및 발모 촉진이 가능한 화합물 및 구체적인 작용 기전에 관한 연구는 미흡한 실정이다.As described above, in addition to changes in hormone secretion, there is an increasing demand for pharmaceutical compositions and cosmetic compositions capable of preventing hair loss and promoting hair growth as the hair loss phenomenon due to stress increases, but a compound capable of effectively preventing hair loss and promoting hair growth And studies on specific mechanisms of action are insufficient.
본 발명에 따른 활성산소 공여체(ROS donor)는 모유두 세포의 증식을 촉진하고 세포 이주능 증가 효과를 나타내며, 털을 제거한 마우스 등에서 발모 촉진 효과를 유의적으로 나타낼 수 있으므로, 탈모 방지 또는 발모 촉진용 약학적 조성물, 화장료 조성물의 유효성분으로 유용하게 사용될 수 있다.The free radical donor (ROS donor) according to the present invention promotes the proliferation of breast papilla cells and shows the effect of increasing cell migration ability, and can significantly exhibit the effect of promoting hair growth in mice with hair removed, etc., thus preventing or preventing hair loss. It can be usefully used as an active ingredient in red compositions and cosmetic compositions.
따라서, 본 발명은 활성산소 공여체(ROS donor)를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 약학적 조성물을 제공한다.Accordingly, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth, which includes an active oxygen donor (ROS donor) as an active ingredient.
본 발명에서, 활성산소 공여체(ROS donor)는 모유두 세포에 활성산소를 제공하여 모유두 세포를 자극시키는 화합물을 의미하며, 모유두 세포의 증식능력, 이동능력 또는 발모능력을 증가시키는 활성산소 공여체라면 제한 없이 포함될 수 있다. In the present invention, an active oxygen donor (ROS donor) refers to a compound that stimulates dermal papilla cells by providing active oxygen to the dermal papilla cells, and is not limited if it is an active oxygen donor that increases the proliferation, migration, or hair growth capacity of the dermal papilla cells. Can be included.
구체적으로, 본 발명의 활성산소 공여체는 로테논(rotenone), 안티마이신(antimycin), 할록시포프(haloxyfop), 다이쿼드(diquat), 젠타마이신(gentamicine), 패러?R(paraquat), 플럼바긴(plumbagin), 저글론(juglone), 스트렙토마이신(streptomycin), 카나마이신(kanamycin), 네오마이신(neomycin), 토브라마이신(tobramycin), 네틸마이신(netilmicin), 파로모마이신(paromomycin), 독소루비신(Doxorubicin), 테가푸르(tegafur), 졸레드론산(zoledronic acid), 옥살리플라틴(oxaliplatin), 테트라케인(Tetracaine), 코카인(cocaine), 벤조카인(benzocaine), 리도카인(lidocaine), 부피바카인(bupivacaine), 레보부피바카인(levobupivacaine), 로피바카인(ropivacaine), 메피바카인(mepivacaine) 및 디부카인(dibucaine) 으로 이루어진 군에서 선택되는 어느 하나 이상일 수 있다.Specifically, the free radical donors of the present invention include rotenone, antimycin, haloxyfop, diquat, gentamicine, para?R, paraquat (plumbagin), juglone, streptomycin, kanamycin, neomycin, tobramycin, netilmicin, paromomycin, doxorubicin ), tegafur, zoledronic acid, oxaliplatin, tetracaine, cocaine, benzocaine, lidocaine, bupivacaine , Levobupivacaine, lepivacaine, mepivacaine and dibucaine.
본 발명에서 사용되는 용어 "탈모 방지" 또는 "발모 촉진"은 동일한 의미로 사용되며, 이는 당업계에서 이용되는 또 다른 용어 양모 또는 육모 촉진과 동일한 의미를 가진다.The terms "prevention of hair loss" or "promote hair growth" as used in the present invention are used in the same sense, which has the same meaning as another term for promoting hair or hair growth in the art.
본 발명에서 사용된 "로테논(rotenone)"은 하기 [화학식 1]로 표시되는 화학구조를 가지며, IUPAC(International Union of Pureand Applied Chemistry) 상 (2R,6aS,12aS)-1,2,6,6a,12,12a-hexahydro-2-isopropenyl-8,9- dimethoxychromeno [3,4-b]furo(2,3-h)chromen-6-one으로 명명된다. 콩과 식물 데리스(Derris elliptica)의 뿌리에서 얻어지는 화학성분으로 미토콘드리아의 호흡 사슬에 작용하는 호흡저해제의 일종으로도 알려져 있다"Rotenone" used in the present invention has a chemical structure represented by the following [Formula 1], IUPAC (International Union of Pureand Applied Chemistry) phase (2R,6aS,12aS)-1,2,6, It is named as 6a,12,12a-hexahydro-2-isopropenyl-8,9-dimethoxychromeno [3,4-b]furo(2,3-h)chromen-6-one. It is a chemical component obtained from the root of the legume derris elliptica, and is also known as a type of respiratory inhibitor acting on the mitochondrial respiratory chain.
[화학식 1][Formula 1]
본 발명에서 사용된 "안티마이신(antimycin)"은 IUPAC 상 (2{R},3{S},6{S},7{R},8{R})-3-[(3-formamido-2-hydroxybenzoyl)amino]-8-hexyl 2,6-dimethyl-4,9-dioxo-1,5-dioxonan-7-yl-3-methylbutanoate로 명명된다. 항진균성 항생물질로서, 미토콘드리아의 전자전달계와 결합하여 시토크롬(cytochrome) b에서 시토크롬 c1으로의 전자전달을 저해하는 것으로 알려져 있으며, 하기 화학식 2의 구조를 가지고 있다."Antimycin" used in the present invention is an IUPAC phase (2{R},3{S},6{S},7{R},8{R})-3-[(3-formamido- 2-hydroxybenzoyl)amino]-8-
[화학식 2][Formula 2]
본 발명에서 사용된 "할록시포프(haloxyfop)"는 하기 [화학식 3]으로 표시되는 화학구조를 가지며, IUPAC 상 2-[4-[(3-클로로-5-트리플루오로메틸-2-피리딜옥시)페녹시]프로피온산)으로 명명된다. 아세틸 CoA 카르복실라제의 억제를 통해 지질의 생합성을 억제하는 것으로 알려져 있다. The "haloxyfop" used in the present invention has a chemical structure represented by the following [Chemical Formula 3], and 2-[4-[(3-chloro-5-trifluoromethyl-2-pyridine on IUPAC) Dioxy)phenoxy]propionic acid). It is known to inhibit the biosynthesis of lipids by inhibiting acetyl CoA carboxylase.
[화학식 3][Formula 3]
본 발명에서 사용된 "다이쿼드(diquat)"는 하기 [화학식 4]로 표시되는 화학구조를 가지는 다이쿼드 디브로마이드(diquat dibromide)를 포함하고, IUPAC 상 6,7-Dihydrodipyrido[1,2-a:2′′c]pyrazinediium dibromide 로 명명된다. 다이쿼드 계열의 화합물들은 현재 국내에서는 생장조절제의 용도로 주로 사용되며, 광계 I(PSI)을 억제하는 기작에 따라 세포 독성을 갖는 N-와 O3 생성을 통해 미토콘드리아를 사멸시키는 특징을 갖는 것으로 알려져 있다."Diquat" used in the present invention includes a diquad dibromide having a chemical structure represented by the following [Formula 4], 6,7-Dihydrodipyrido [1,2- a on IUPAC :2′′ c ]pyrazinediium dibromide. Diquad-based compounds are currently mainly used for growth regulators in Korea, and are known to have the characteristic of killing mitochondria through the production of N- and O 3 with cytotoxicity according to the mechanism of suppressing the photosystem I (PSI). have.
[화학식 4][Formula 4]
본 발명에서 사용된 "젠타마이신(gentamicine)"은 IUPAC 상 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2-hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol로 명명된다. 광범위한 항생제로, 단백질의 생리 활성을 억제하는 것으로 알려져 있다.As used in the present invention, "gentamicine" is 2-[4,6-diamino-3-[3-amino-6-[1-(methylamino)ethyl]oxan-2-yl]oxy-2 on IUPAC. -hydroxycyclohexyl]oxy-5-methyl-4-(methylamino)oxane-3,5-diol. A wide range of antibiotics, it is known to inhibit the physiological activity of proteins.
본 발명의 일실시예에서, 본 발명자들은 활성산소 공여체를 대표하여 로테논(rotenone), 안티마이신(antimycin), 할록시포프(haloxyfop), 다이쿼드(diquat), 젠타마이신(gentamicine)을 모유두 세포에 처리하였을 때 모유두 세포의 증식능력, 이동능력, 생존능력 및 발모능력이 향상되는 것을 확인하였다.In one embodiment of the present invention, the present inventors represent rotenone, antimycin, haloxyfop, diquat, and gentamicine as a representative of an active oxygen donor in all papilla cells. It was confirmed that proliferation, migration, viability and hair growth of the papillary cells were improved when treated with.
이에, 본 발명의 활성산소 공여체는 모유두 세포의 증식 촉진, 이동능 증가, 수명 연장 및 발모를 촉진하는 활성을 갖는 것일 수 있다.Thus, the free radical donor of the present invention may have an activity to promote proliferation of breast papilla cells, increase mobility, prolong life and promote hair growth.
본 발명의 다른 일실시예에서는 활성산소 공여체의 농도에 따른 모유두 세포의 성장 촉진 및 모발유도능력 향상 효과를 ELISA를 이용하여 측정하였다. 로테논의 경우 10pM 처리시 대조군 대비 40% 이상 세포 증식능력이 상승하였으며, 2.5배 이상의 세포 이동능력 증가 효과를 나타내고, 동물모델에서 1nM의 로테논을 14일 동안 피부에 흡수시켰을 때 대조군 대비 3배 이상 발모 효과가 나타남을 확인하였다. 안티마이신의 경우도 10pM 이상 처리시 대조군 대비 세포 증식능력이 상승하였으며, 세포 이동능력 증가 효과를 나타내고, 동물모델에서 1uM의 로테논을 14일 동안 피부에 흡수시켰을 때 대조군 대비 약 2배 이상 발모 효과가 나타남을 확인하였다.In another embodiment of the present invention, the effect of promoting growth of hair papilla cells and improving hair inducing ability according to the concentration of free radical donors was measured using ELISA. In the case of rotenone, the cell proliferation capacity increased by 40% or more compared to the control group when treated with 10 pM, and showed an effect of increasing cell migration capacity by 2.5 times or more, and 3 times or more compared to the control group when 1 nM of rotenone was absorbed into the skin for 14 days in the animal model. It was confirmed that the hair growth effect appeared. In the case of antimycin, the cell proliferation ability was increased compared to the control group when treated with 10 pM or more, and the effect of increasing the cell migration capacity was increased, and when the 1 uM rotenone was absorbed into the skin for 14 days in the animal model, the hair growth effect was about 2 times higher than the control group. It was confirmed that appears.
이에, 활성산소 공여체는 본 발명의 탈모 방지 또는 발모 촉진용 조성물에 0.1nM 이상 10nM 이하의 농도로 포함되어 있을 수 있고, 0.1pM 이상 1pM 이하로 함유되어 있을 수 있으나, 이에 제한되는 것은 아니다.Thus, the active oxygen donor may be contained in a concentration of 0.1 nM or more and 10 nM or less in the composition for preventing hair loss or promoting hair growth of the present invention, and may be contained in a concentration of 0.1 pM or more and 1 pM or less, but is not limited thereto.
조성물의 농도가 상기 농도 미만인 경우 탈모 방지 또는 발모 촉진 효과가 미비하다는 문제점이 있고, 상기 농도를 초과하는 경우 세포독성의 문제점이 있다.When the concentration of the composition is less than the concentration, there is a problem that the effect of preventing hair loss or promoting hair growth is insufficient, and when it exceeds the concentration, there is a problem of cytotoxicity.
본 발명의 상기 활성산소 공여체 화합물은 약학적으로 허용 가능한 염의 형태로 사용할 수 있고, 본 발명의 활성산소 공여체는 통상의 방법에 의해 제조될 수 있는 모든 염, 수화물 및 용매화물을 모두 포함한다.The free radical donor compound of the present invention can be used in the form of a pharmaceutically acceptable salt, and the free radical donor of the present invention includes all salts, hydrates and solvates that can be prepared by conventional methods.
본 발명의 활성산소 공여체를 유효성분으로 포함하는 약학적 조성물은 탈모 방지 및 발모 개선, 촉진용 피부외용제로서 크림, 젤, 패치, 분무제, 연고제, 경고제, 로션제, 리니멘트제, 파스타제 또는 카타플라즈마제의 피부 외용제 형태의 약학조성물로 제조하여 사용할 수 있으나, 이에 제한되는 것은 아니다.The pharmaceutical composition comprising the active oxygen donor of the present invention as an active ingredient is a skin external agent for preventing hair loss and improving hair growth and promoting cream, gel, patch, spray, ointment, warning, lotion, linen, pasta, or Cataplasma may be prepared and used as a pharmaceutical composition in the form of an external preparation for skin, but is not limited thereto.
또한, 본 발명은 활성산소 공여체를 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 화장료 조성물을 제공한다. 상기 활성산소 공여체의 구체적인 내용은 전술한 바와 같다.In addition, the present invention provides a cosmetic composition for preventing hair loss or promoting hair growth comprising an active oxygen donor as an active ingredient. Details of the active oxygen donor are as described above.
본 발명의 화장료 조성물에 포함되는 성분은 유효 성분으로서의 활성산소 공여체 이외에 화장품 조성물에 통상적으로 이용되는 성분들을 포함하며, 예컨대 항산화제, 안정화제, 용해화제, 비타민, 안료 및 향료와 같은 통상적인 보조제, 그리고 담체를 포함한다.The ingredients included in the cosmetic composition of the present invention include ingredients commonly used in cosmetic compositions in addition to the active oxygen donor as an active ingredient, for example, conventional adjuvants such as antioxidants, stabilizers, solubilizers, vitamins, pigments and fragrances, And carriers.
본 발명의 화장료 조성물은 당업계에서 통상적으로 제조되는 어떠한 제형으로도 제조될 수 있으며, 예를 들어, 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이 등으로 제형화 될 수 있으나, 이에 한정되는 것은 아니다.The cosmetic composition of the present invention may be prepared in any formulation conventionally prepared in the art, for example, solution, suspension, emulsion, paste, gel, cream, lotion, powder, soap, surfactant-containing cleaning , May be formulated as an oil, powder foundation, emulsion foundation, wax foundation and spray, but is not limited thereto.
다른 측면에서, 본 발명은 활성산소 공여체를 배지에 첨가하여 배양된 모유두 세포 또는 그 배양액을 유효성분으로 포함하는 탈모 방지 또는 발모 촉진용 약학적 조성물을 제공한다. 상기 활성산소 공여체의 구체적인 내용은 전술한 바와 같다.In another aspect, the present invention provides a pharmaceutical composition for preventing hair loss or promoting hair growth, wherein the active oxygen donor is added to the medium to include hair papilla cells cultured or a culture medium thereof as an active ingredient. Details of the active oxygen donor are as described above.
상기 조성물은 세포 이식 용도로 사용될 수 있다.The composition can be used for cell transplantation.
본 발명의 일 실시예에서는 모유두 세포의 배양과정에서 상기 활성산소 공여체를 처리한 후 동물모델에 피하주사하고 14일 경과 후 새로 자란 털을 밀고 무게를 측정하여 본 결과 활성산소 공여체를 전 처리하여 배양한 모유두 세포를 이식하였을 때 대조군 대비 발모 효과가 향상됨을 확인하였다. 구체적으로, 로테논을 10pM 처리시 대조군 대비 3배 이상 발모 효과가 상승하였으며, 안티마이신을 10 nM 처리시 대조군 대비 3배 이상 발모 효과가 상승함을 확인하였다.In one embodiment of the present invention, after treating the active oxygen donor in the process of culturing the papillary cells, the animal model is injected subcutaneously, and after 14 days, the newly grown hair is pushed and the weight is measured. As a result, the active oxygen donor is pretreated and cultured. It was confirmed that when hair follicle cells were transplanted, the hair growth effect was improved compared to the control group. Specifically, it was confirmed that the hair growth effect was increased by 3 times or more compared to the control group when treated with 10 pM of rotenone, and the hair growth effect was increased by 3 times or more compared to the control group when treated with 10 nM antimycin.
또 다른 측면에서, 본 발명은 활성산소 공여체(ROS donor)가 첨가된 배지에서 모유두 세포를 배양하는 단계를 포함하는 모유두 세포의 증식방법을 제공한다. 상기 활성산소 공여체의 구체적인 내용은 전술한 바와 같다.In another aspect, the present invention provides a method for proliferating a papillary cell, comprising culturing the papillary cell in a medium to which a free radical donor (ROS donor) has been added. Details of the active oxygen donor are as described above.
본 발명의 모유두 세포의 증식방법에 있어서, 상기 활성산소 공여체는 모유두 세포의 증식 촉진, 이동능 증가, 수명 연장 및 모발유도를 촉진하는 활성을 갖는 것일 수 있다.In the method of proliferating a papillary cell of the present invention, the free radical donor may have an activity that promotes proliferation of the papillary cells, increases mobility, prolongs life and promotes hair induction.
본 발명의 일실시예에서는 모유두 세포를 FDPG 배지에서 하룻밤 동안 배양하고, 활성산소 공여체를 농도별로 처리한 후 48시간 동안 추가 배양하여 수득한 모유두 세포의 증식능력, 이동능력 및 모발 유도능력의 증가 효과를 확인하였다.In one embodiment of the present invention, the papillary cells are cultured overnight in FDPG medium, and the free radical donor is treated for each concentration and then further cultured for 48 hours to increase the proliferation, migration, and hair inducing effects of the dermal papilla cells. Was confirmed.
따라서, 본 발명은 할성산소 공여체를 유효성분으로 포함하는 모유두 세포 배양용 배지 조성물을 제공한다.Accordingly, the present invention provides a medium composition for culturing a papillary cell comprising a hydrogen-containing donor as an active ingredient.
본 발명에서 배지 조성물이란 모유두 세포를 배양할 수 있는 일반적인 배지 조성물에 상기 활성산소 공여체를 추가로 포함하는 배지 조성물을 의미하고, 나아가 상기 배지 조성물에서 모유두 세포를 배양한 후 상기 모유두 세포를 제거한 용액을 포함하는 조성물도 본 발명의 배지 조성물에 포함될 수 있다.In the present invention, the medium composition refers to a medium composition further comprising the active oxygen donor in a general medium composition capable of culturing the dermal papilla cells, and further, after culturing the dermal papilla cells in the medium composition, a solution in which the papillary cells are removed The composition comprising may also be included in the medium composition of the present invention.
이하, 실시예를 통하여 본 발명을 더욱 상세하게 설명하고자 한다. 이들 실시예는 오로지 본 발명을 예시하기 위한 것으로서, 본 발명의 범위가 이들 실시예에 의해 제한되는 것으로 해석되지 않는 것은 당업계에서 통상의 지식을 가진 자에게 있어서 자명할 것이다.Hereinafter, the present invention will be described in more detail through examples. These examples are only for illustrating the present invention, it will be apparent to those skilled in the art that the scope of the present invention is not to be construed as limited by these examples.
활성산소 공여체의 처리가 모유두 세포의 증식에 미치는 효과Effects of treatment of free radical donors on proliferation of dermal papilla cells
<1-1> 로테논의 모유두 세포 증식 촉진 효과의 확인<1-1> Confirmation of the effect of rotenone on the proliferation of dermal papilla cells
PromoCell로부터 구입한 인간 유래의 모유두 세포(Human dermal papilla cell, hDPC)를 1% 안티바이오틱(Antibiotic) 및 안티마이코틱 (Antimycotic) Hyclone sv30079.91을 포함하는 Follicle Dermal Papilla cell Growth media (Promocell, Heidelberg, Germany) 배지에 접종하고, 37℃의 5% 이산화탄소 배양기에서 배양하여 세포를 준비하였다. 96-well에 준비한 hDPC를 1Х103/well농도로 Follicle Dermal Papilla cell Growth media에 접종하였다. 하룻밤 동안 배양한 후, 로테논(Sigma, USA)을 농도별로(1, 10, 100, 1000pM) 처리한 후 48 시간 동안 추가 배양하였다. 그런 다음, 각 well에 있는 배양 배지를 제거한 후 10 μL의 CCK8 reagent와 90 μL 의 PBS를 첨가하고 2시간 동안 37℃ 온도에서 배양한 후 상층액을 ELISA 리더기를 사용하여 450 ㎚에서 흡광도를 측정하여 세포 증식 정도를 확인하였다.Follicle Dermal Papilla cell growth media (Promocell, Heidelberg) containing human dermal papilla cell (hDPC) derived from PromoCell containing 1% Antibiotic and Antibiotic Hyclone sv30079.91 , Germany) Inoculated into the medium, and cultured in a 5% carbon dioxide incubator at 37°C to prepare cells. HDPC prepared in 96-well was inoculated into Follicle Dermal Papilla cell growth media at a concentration of 1Х10 3 /well. After incubation overnight, Rotenone (Sigma, USA) was treated by concentration (1, 10, 100, 1000 pM) and further incubated for 48 hours. Then, after removing the culture medium in each well, after adding 10 μL of CCK8 reagent and 90 μL of PBS and incubating at 37° C. for 2 hours, the supernatant was measured at 450 nm using an ELISA reader. The degree of cell proliferation was confirmed.
그 결과, [도 1a]에 나타난 바와 같이 로테논을 처리한 경우 특정 농도범위에서 대조군 대비 모유두 세포의 증식이 증가하였다.As a result, proliferation of dermal papilla cells was increased in a specific concentration range when treated with rotenone as shown in [Fig. 1a].
<1-2> 안티마이신의 모유두 세포 증식 촉진 효과의 확인<1-2> Confirmation of the effect of antimycin on the proliferation of dermal papilla cells
인간 유래의 모유두 세포(Human dermal papilla cell, hDPC)를 1% 안티바이오틱(Antibiotic) 및 안티마이코틱 (Antimycotic) Hyclone sv30079.91을 포함하는 Follicle Dermal Papilla cell Growth media (Promocell, Heidelberg, Germany) 배지에 접종하고, 37℃의 5% 이산화탄소 배양기에서 배양하여 세포를 준비하였다. 96-well에다가 준비한 hDPC를 1Х103/well농도로 배양배지에 접종하였다. 하룻밤 동안 배양한 후, 각 농도(1nM, 10nM, 100nM, 1000nM)의 안티마이신을 처리하여 48 시간 동안 추가 배양하였다. 그런 다음, 트립신으로 각 well에 세포를 띄운 후 원심분리 하였다. 상층액을 버리고 밑층에 세포만 남겨두었다. 1X PBS를 첨가하여 세포를 잘 풀어준 후 트리판불루로 염색하였다. 공식을 이용하여 세포수를 계산해서 세포 증식 정도를 확인하였다. Follicle Dermal Papilla cell growth media (Promocell, Heidelberg, Germany) medium containing 1% Antibiotic and Antimyotic Hyclone sv30079.91 containing human dermal papilla cell (hDPC) And incubated in a 5% carbon dioxide incubator at 37°C to prepare cells. The hDPC prepared in 96-well was inoculated into the culture medium at a concentration of 1Х10 3 /well. After incubation overnight, each concentration (1nM, 10nM, 100nM, 1000nM) was treated with antimycin to further incubate for 48 hours. Then, cells were floated in each well with trypsin and centrifuged. The supernatant was discarded, leaving only the cells in the bottom layer. The cells were well released by adding 1X PBS and stained with trypanbulu. The number of cells was calculated using the formula to confirm the degree of cell proliferation.
그 결과 [도 1b]에 나타난 바와 같이 특정 농도 이상으로 안티마이신을 처리한 경우 모유두 세포의 증식이 증가함을 확인할 수 있었다.As a result, as shown in [Fig. 1b], when antimycin was treated at a specific concentration or higher, it was confirmed that proliferation of the papillary cells increased.
<1-3> 할록시포프, 다이쿼드 및 젠타마이신의 모유두 세포 증식 촉진 효과 확인<1-3> Confirmation of the effect of promoting the proliferation of dermal papilla cells by haloxop, diquad and gentamicin
인간 유래의 모유두 세포(Human dermal papilla cell, hDPC)를 1% 안티바이오틱(Antibiotic) 및 안티마이코틱 (Antimycotic) Hyclone sv30079.91을 포함하는 Follicle Dermal Papilla cell Growth media (Promocell, Heidelberg, Germany) 배지에 접종하고, 37℃의 5% 이산화탄소 배양기에서 배양하여 세포를 준비하였다. 96-well에 준비한 hDPC를 1Х103/well농도로 Follicle Dermal Papilla cell Growth media에 접종하였다. 하룻밤 동안 배양한 후, 할록시포프(haloxyfop), 다이쿼드(diquat) 및 젠타마이신(gentamicine) 각각을 농도별로(1pM, 10pM, 1nM, 100nM, 10μM) 처리한 후 48 시간 동안 추가 배양하였다. 그런 다음, 각 well에 있는 배양 배지를 제거한 후 10 μL의 CCK8 reagent와 90 μL 의 PBS를 첨가하고 2시간 동안 37℃ 온도에서 배양한 후 상층액을 ELISA 리더기를 사용하여 450 ㎚에서 흡광도를 측정하여 세포 증식 정도를 확인하였다.Follicle Dermal Papilla cell growth media (Promocell, Heidelberg, Germany) medium containing 1% Antibiotic and Antimyotic Hyclone sv30079.91 containing human dermal papilla cell (hDPC) And incubated in a 5% carbon dioxide incubator at 37°C to prepare cells. HDPC prepared in 96-well was inoculated into Follicle Dermal Papilla cell growth media at a concentration of 1Х10 3 /well. After incubation overnight, each of haloxyfop, diquat and gentamicin was treated by concentration (1 pM, 10 pM, 1 nM, 100 nM, 10 μM), followed by further incubation for 48 hours. Then, after removing the culture medium in each well, 10 μL of CCK8 reagent and 90 μL of PBS were added and incubated at 37° C. for 2 hours, and the supernatant was measured at 450 nm using an ELISA reader. The degree of cell proliferation was confirmed.
그 결과, [도 1c] 내지 [도 1e]에 나타난 바와 같이 할록시포프, 다이쿼드 또는 젠타마이신을 처리한 경우 특정 농도범위에서 대조군 대비 모유두 세포의 증식이 증가하였다.As a result, as shown in [Figure 1c] to [Figure 1e], proliferation of dermal papilla cells increased compared to the control group in a specific concentration range when treated with haloxophop, diquad, or gentamicin.
활성산소 공여체의 처리가 모유두 세포의 이동에 미치는 효과Effect of treatment of free radical donors on the migration of dermal papilla cells
<2-1> 로테논의 모유두 세포 이주능(cell migration) 촉진 효과의 확인<2-1> Confirmation of Rotenone's Effect on Promoting Cell Migration
60mm 배양접시에 세포를 5Х105농도로 접종하였다. 하룻밤 동안 배양한 후 블루(1000μL)팁을 이용하여 접시 바닥에 스크래치를 내주었다. 각 농도의 로테논을 처리하여 48 시간 동안 추가 배양하였다. 양쪽의 세포들은 스크래치 중간 위치를 향해 이동한 거리를 측정 하여, 세포 이주능을 확인하였다.Cells were inoculated at 5Х10 5 concentration in a 60mm culture dish. After incubation overnight, a blue (1000 μL) tip was used to scratch the bottom of the dish. Each concentration of rotenone was treated and further incubated for 48 hours. Cells on both sides were confirmed for cell migration ability by measuring the distance traveled toward the middle of the scratch.
그 결과, [도 2a]에 나타난 바와 같이 로테논을 처리한 경우 모유두 세포의 이동이 증가하였으며, 특정 농도범위로 로테논을 처리하였을 때 모유두 세포의 이동거리가 월등하게 증가함을 확인할 수 있었다.As a result, as shown in FIG. 2A, when the rotenone was treated, the migration of the dermal papilla cells increased, and when the rotenone was treated in a specific concentration range, it was confirmed that the migration distance of the dermal papilla cells was significantly increased.
<2-2> 안티마이신의 모유두 세포 이주능(cell migration) 촉진 효과의 확인<2-2> Confirmation of Antimycin's Effect on Promoting Cell Migration
60mm 배양접시에 세포를 5Х105농도로 접종하였다. 하룻밤 동안 배양한 후 블루(1000μL)팁을 이용하여 접시 바닥에 스크래치를 내주었다. 각 농도의 안티마이신을 처리하여 48 시간 동안 추가 배양하였다. 양쪽의 세포들은 스크래치 중간 위치를 향해 이동한 거리를 측정 하여, 세포 이주능을 확인하였다. Cells were inoculated at 5Х10 5 concentration in a 60mm culture dish. After incubation overnight, a blue (1000 μL) tip was used to scratch the bottom of the dish. Each concentration of antimycin was treated to further incubate for 48 hours. Cells on both sides were confirmed for cell migration ability by measuring the distance traveled toward the middle of the scratch.
그 결과 [도 2b]에 나타난 바와 같이 안티마이신을 처리한 경우 모유두 세포의 이동이 증가하였으며, 특정 농도범위로 안티마이신을 처리하였을 때 모유두 세포의 이동거리가 월등하게 증가함을 확인할 수 있었다.As a result, as shown in FIG. 2B, when the antimycin treatment was performed, the migration of the dermal papilla cells increased, and when the antimycin treatment was performed in a specific concentration range, the migration distance of the dermal papilla cells was significantly increased.
생체 내에서 활성산소 공여체의 처리가 발모에 미치는 효과Effect of treatment of free radical donors on hair growth in vivo
<3-1> 생체 내에서 로테논에 의한 발모 촉진 효과의 확인<3-1> Confirmation of the effect of promoting hair growth by rotenone in vivo
애완동물용 털 제모기와 제모크림을 사용해서 6주령 female C3H 쥐의 등 부분의 털을 제거한 후 0.1 nM, 1 nM의 로테논을 100 μL씩 쥐 등에 14일 동안 발라주었다. 14일 후 면도칼을 사용하여 쥐 등에 새로 자란 털을 밀고 무게측정을 통해서 털 재생하는 정도를 살펴보았다.After removing the hair on the back of a 6-week-old female C3H rat using a pet hair depilator and a hair removal cream, 100 μL of 0.1 nM, 1 nM rotenone was applied to the rats for 14 days. After 14 days, a razor was used to push newly grown hair on the rat back and the degree of hair regeneration through weight measurement was examined.
그 결과, [도 3a] 에 나타난 바와 같이, 모발의 성장기 유도는 로테논을 직접 쥐의 등에 바른 부위에 피부의 다크닝 또는 모발 재생이 나타났다. As a result, as shown in [Fig. 3a], the growth phase induction of hair showed darkening of the skin or hair regeneration in the area where rotenone was directly applied to the rat's back.
<3-2> 생체 내에서 안티마이신의 발모 촉진 효과의 확인<3-2> Confirmation of anti-mycin hair growth promoting effect in vivo
애완동물용 털 제모기와 제모크림을 사용해서 6주령 female C3H쥐의 등 부분의 털을 제거한 후 0.1μM, 1μM의 안티마이신을 100μL씩 쥐 등에 14일 동안 발라주었다. 14일 후 면도칼을 사용하여 쥐 등에 새로 자란 털을 밀고 무게측정을 통해서 털 재생하는 정도를 살펴보았다.After removing hair from the back of a 6-week-old female C3H rat using a pet hair depilator and a hair removal cream, 0.1 μM and 1 μM of antimycin were applied to rats for 14 days. After 14 days, a razor was used to push newly grown hair on the rat back and the degree of hair regeneration through weight measurement was examined.
그 결과 [도 3b] 에 나타난 바와 같이 모발의 성장기 유도는 안티마이신을 직접 쥐의 등에 바른 부위에 피부의 다크닝 또는 모발 재생이 나타났다. As a result, as shown in [Fig. 3b], the growth phase induction of hair showed darkening of the skin or hair regeneration in the area where antimycin was directly applied to the rat's back.
생체 내에서 활성산소 공여체로 전 처리된(Pre-treatment) 모유두 세포가 발모에 미치는 효과Effect of pre-treatment of dermal papilla cells on hair growth in vivo with free radical donors
<4-1> 생체 내에서 로테논으로 전 처리된 모유두 세포의 발모 촉진 효과의 확인<4-1> Confirmation of the hair growth promoting effect of dermal papilla cells pretreated with rotenone in vivo
로테논으로 전 처리된 모유두 세포를 이식하였을 때의 발모 효과를 확인하기 위하여 추가 실험을 진행하였다. 100mm 배양 접시에 인간 유래의 모유두 세포(Human dermal papilla cell, hDPC)를 1Х106농도로 접종하고 하루 동안 배양한 후 10 pM의 로테논을 24시간 처리 하였다. 그런 다음, 트립신으로 세포를 띄운 후 원심분리를 통해서 상층액을 버리고 아래 층에 세포만 남겨두었다. 1ml의 PBS를 첨가하고 세포를 잘 풀어주었다. 트리판 블루 염색해서 세포 수를 세었다. 공식을 이용해서 계산한 후 1x106의 세포를 피펫으로 새 튜브로 옮긴 후 다시 원심분리 하였다. 상층액을 제거하고 100 μL의 PBS를 첨가하여 세포를 잘 풀어주었다. 6주령 female C3H쥐의 등 부분의 털을 제거한 후 100μL의 DMSO 및 10 pM의 로테논을 처리한 hDPC를 피하주사를 하였다. 모발주기가 유도되는 표시인 피부 다크닝 (darkning)을 모니터링하고, 14일 후 등에 새로 자란 털을 밀고 무게 측정을 통해서 털 재생하는 정도를 살펴보았다.Additional experiments were conducted to confirm the hair growth effect when the papillary cells pretreated with rotenone were transplanted. Human dermal papilla cells (hDPC) derived from humans were inoculated at 100 mm culture dishes at a concentration of 1 Х10 6 and cultured for one day, followed by treatment with 10 pM of rotenone for 24 hours. Then, after floating the cells with trypsin, the supernatant was discarded through centrifugation, and only the cells were left in the lower layer. 1 ml of PBS was added and the cells were well released. Cells were counted by trypan blue staining. After counting using the formula, 1x10 6 cells were transferred to a new tube with a pipette and centrifuged again. The supernatant was removed and 100 μL of PBS was added to release the cells well. After removing the hair from the back of a 6-week-old female C3H rat, hDPC treated with 100 μL DMSO and 10 pM rotenone was injected subcutaneously. We monitored the skin darkning, a sign that the hair cycle is induced, and examined the degree of hair regeneration by pushing the newly grown hair on the back 14 days later and weighing it.
그 결과, [도 4a]에 나타난 바와 같이 모발의 성장기 유도는 로테논 처리되지 않은 모유두 세포를 투여한 생쥐(대조군)보다 로테논이 전 처리된 모유두 세포를 투여한 생쥐가, 14일 경과 후에 등 부분의 모발이 성장하여 등 부분을 덮은 것을 확인할 수 있다. 모발의 무게는 로테논으로 전 처리된 모유두 세포에서 대조군 대비 새로 자란 털의 무게가 3배 이상 증가하였다.As a result, as shown in [Fig. 4a], the growth phase induction of hair was observed in 14 days after the rats that received the papillary cells pre-treated with rotenone than the mice that received the papillary cells that were not treated with rotenone (control). It can be seen that the hair of the portion grew and covered the back portion. The hair weight of the papillary cells pretreated with rotenone increased more than three times the weight of newly grown hair compared to the control group.
<4-2> 생체 내에서 안티마이신으로 전 처리된 모유두 세포의 발모 촉진 효과의 확인<4-2> Confirmation of the hair growth promoting effect of dermal papilla cells pretreated with antimycin in vivo
안티마이신으로 전 처리된 모유두 세포를 이식하였을 때의 발모 효과를 확인하기 위하여 추가 실험을 진행하였다. 100mm 배양 접시에 1Х106농도로 접종하고 하루 동안 배양한 후 0.1%의 DMSO 와 10 nM의 안티마이신을 24시간 처리 하였다. 그런 다음, 트립신으로 세포를 띄운 후 원심분리를 통해서 상층액을 버리고 밑에 층에 세포만 남겨두었다. 1ml의 PBS를 첨가하고 세포를 잘 풀어주었다. 트리판블루 염색해서 세포 수를 세었다. 공식을 이용해서 계산한 후 1x106의 세포를 피펫으로 새 튜브로 옮긴 후 다시 원심분리 하였다. 상층액을 제거하고 100 μL의 PBS를 첨가하여 세포를 잘 풀어주었다. 6 주령 female C3H쥐의 등부분의 털을 제거한 후 100μL의 DMSO 및 10 nM의 안티마이신을 처리한 hDPC를 피하주사를 하였다. 14일 후 등에 새로 자란 털을 밀고 무게 측정을 통해서 털 재생하는 정도를 살펴보았다.Additional experiments were conducted to confirm the hair growth effect when the breast papilla cells pretreated with antimycin were transplanted. After inoculating at a concentration of 1Х10 6 in a 100mm culture dish, and cultured for one day, 0.1% DMSO and 10 nM antimycin were treated for 24 hours. Then, after floating the cells with trypsin, the supernatant was discarded through centrifugation, and only the cells were left in the lower layer. 1 ml of PBS was added and the cells were well released. Cells were counted by trypan blue staining. After counting using the formula, 1x10 6 cells were transferred to a new tube with a pipette and centrifuged again. The supernatant was removed and 100 μL of PBS was added to release the cells well. After removing the hair on the back of a 6-week-old female C3H rat, hDPC treated with 100 μL of DMSO and 10 nM antimycin was injected subcutaneously. After 14 days, we looked at the degree of hair regeneration by pushing the newly grown hair and weighing it.
그 결과, [도 4b]에 나타난 바와 같이 모발의 성장기 유도는 모유두 세포 단독 처리 대조군 과는 달리 안티마이신을 전 처리된 모유두 세포를 투여한 생쥐의 경우, 14일 경과 후에 등부분의 모발이 성장하여 등 부분을 덮은 것을 확인할 수 있다. 모발의 무게는 안티마이신으로 전 처리된 모유두 세포에서 3배이상 증가하였다.As a result, as shown in [Fig. 4b], in the case of the mice in which the anti-mycin pre-treated breast papilla cells were administered, unlike the control group treated with the papillary cells alone, the hair of the dorsal part grew after 14 days. It can be seen that the back portion was covered. The weight of the hair increased more than 3 times in the papillary cells pretreated with antimycin.
Claims (10)
로테논에 의해 모유두 세포의 증식 촉진, 이동능 증가, 수명연장 및 모발유도능력이 증가하여 발모가 유도되는 것을 특징으로 하는 탈모 방지 또는 발모 촉진용 약학적 조성물.
Contains rotenone as an active ingredient,
A pharmaceutical composition for preventing hair loss or promoting hair growth, characterized in that hair growth is induced by promoting proliferation of breast papilla cells, increasing mobility, prolonging life, and increasing hair inducing capacity by rotenone.
로테논에 의해 모유두 세포의 증식 촉진, 이동능 증가, 수명연장 및 모발유도능력이 증가하여 발모가 유도되는 것을 특징으로 하는 탈모 개선 또는 발모 촉진용 화장료 조성물.
Contains rotenone as an active ingredient,
A cosmetic composition for improving hair loss or promoting hair growth, characterized in that hair growth is induced by promoting proliferation of breast papilla cells, increasing mobility, extending life, and increasing hair inducing capacity by rotenone.
상기 조성물은 용액, 현탁액, 유탁액, 페이스트, 겔, 크림, 로션, 파우더, 비누, 계면활성제-함유 클린싱, 오일, 분말 파운데이션, 유탁액 파운데이션, 왁스 파운데이션 및 스프레이로 구성된 군으로부터 선택되는 제형을 갖는 것을 특징으로 하는, 화장료 조성물.
According to claim 4,
The composition has a formulation selected from the group consisting of solutions, suspensions, emulsions, pastes, gels, creams, lotions, powders, soaps, surfactant-containing cleansing, oils, powder foundations, emulsion foundations, wax foundations and sprays Characterized in that, cosmetic composition.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| KR20180023990 | 2018-02-27 | ||
| KR1020180023990 | 2018-02-27 |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200070274A Division KR102158584B1 (en) | 2018-02-27 | 2020-06-10 | Composition for culturing dermal papilla cell comprising ROS donor as an active ingredient and uses thereof |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| KR20190103057A KR20190103057A (en) | 2019-09-04 |
| KR102138241B1 true KR102138241B1 (en) | 2020-07-28 |
Family
ID=67950151
Family Applications (3)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020190022918A KR102138241B1 (en) | 2018-02-27 | 2019-02-27 | Composition for the preventing loss of hair and promoting growth of hair comprising rotenone as an active ingredient |
| KR1020200070274A KR102158584B1 (en) | 2018-02-27 | 2020-06-10 | Composition for culturing dermal papilla cell comprising ROS donor as an active ingredient and uses thereof |
| KR1020200115228A KR20200109281A (en) | 2018-02-27 | 2020-09-09 | Composition for the preventing loss of hair and promoting growth of hair comprising dermal papilla cells cultured in a medium containing an ROS donor |
Family Applications After (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020200070274A KR102158584B1 (en) | 2018-02-27 | 2020-06-10 | Composition for culturing dermal papilla cell comprising ROS donor as an active ingredient and uses thereof |
| KR1020200115228A KR20200109281A (en) | 2018-02-27 | 2020-09-09 | Composition for the preventing loss of hair and promoting growth of hair comprising dermal papilla cells cultured in a medium containing an ROS donor |
Country Status (1)
| Country | Link |
|---|---|
| KR (3) | KR102138241B1 (en) |
Families Citing this family (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| KR102583168B1 (en) | 2020-11-27 | 2023-09-26 | (주)엑셀세라퓨틱스 | Media composition for growing dermal papilla cells comprising rotenone and albumin as active ingredients |
| KR102561912B1 (en) * | 2021-04-09 | 2023-07-31 | 차의과학대학교 산학협력단 | Cephalothin derivative or pharmaceutically acceptable salt thereof, process for the preparation thereof and composition for preventing hair loss or promoting hair growth comprising the same |
| KR102663430B1 (en) * | 2021-08-18 | 2024-05-17 | 강다윗 | Composition for improving hair loss containing personalized dermal papilla cell culture medium |
-
2019
- 2019-02-27 KR KR1020190022918A patent/KR102138241B1/en active IP Right Grant
-
2020
- 2020-06-10 KR KR1020200070274A patent/KR102158584B1/en active IP Right Grant
- 2020-09-09 KR KR1020200115228A patent/KR20200109281A/en not_active Application Discontinuation
Non-Patent Citations (2)
| Title |
|---|
| Sci Signal. 6(261), 2014. (2014.5.12)* |
| THE JOURNAL OF BIOLOGICAL CHEMISTRY 278(38) pp. 36027-36031, 2003 (2003.7.2.)* |
Also Published As
| Publication number | Publication date |
|---|---|
| KR102158584B1 (en) | 2020-09-22 |
| KR20200109281A (en) | 2020-09-22 |
| KR20200074922A (en) | 2020-06-25 |
| KR20190103057A (en) | 2019-09-04 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| KR102158584B1 (en) | Composition for culturing dermal papilla cell comprising ROS donor as an active ingredient and uses thereof | |
| US9820933B2 (en) | Composition for stimulating hair growth or preventing hair loss which includes extract neural stem cell and method for producing same | |
| WO2007061168A1 (en) | Pharmaceutical compositions for cell therapy of pigmentation disorders | |
| KR20130135164A (en) | Agent for improving skin regeneration and hair growing comprising leontopodium alpinum extracts | |
| KR20120034167A (en) | Method and compositions for increasing trichogenic potency of dermal cells | |
| KR20190127553A (en) | Method for preparing dermal papilla cell and cell spheroid under hypoxic culture condition | |
| WO2017064672A1 (en) | A method and composition to differentiate mesenchymal stem cells into melanocytes | |
| KR20150067130A (en) | Tissue-preserving liquid and tissue-preserving method | |
| US20140039204A1 (en) | 7'-phloroeckol compound for hair proliferation and a cosmetic composition containing same | |
| KR102406000B1 (en) | Composition for promoting hair growth and/or restoration containing soyasaponin | |
| CN106794192B (en) | Composition for preventing hair loss or promoting hair growth comprising oleanolic acid derivative and pharmaceutically acceptable salt thereof | |
| KR101902425B1 (en) | Agent for improving regeneration comprising Gardenia jasminodes extracts | |
| JP7092886B2 (en) | Embryonic lobe pluripotent stem cells, neural stem cells, embryonic fibroblasts, which are cells isolated from avian eggs. Medium composition for cell proliferation, skin regeneration, and wrinkle improvement using a conditioned medium as an active ingredient. | |
| KR101693923B1 (en) | Anti-inflammation and Anti-aging composition for skin external application comprising Zostera marina Cell Culture Extract and Methods for preparing the Same | |
| JP2006273754A (en) | Hair restorer having diosgenin and its derivative as active ingredient | |
| CN115317393A (en) | Methods and compositions for improving hair follicle, scalp or hair health in mammals | |
| KR101570004B1 (en) | Composition for promoting growth of hair | |
| KR20170110910A (en) | Hair growth activating composition comprising leaf extract of conifer containing pinane | |
| KR20160064954A (en) | Method for promoting growth of hair | |
| KR20200071043A (en) | Composition for preventing hair loss or promoting hair growth comprising epireguline or epiregulin-derived peptide as an active ingredient | |
| JP2016204297A (en) | Fgf-7 production promoting agent and dermal papilla cell growth-promoting agent | |
| JP7205880B2 (en) | MELANOCYTE DIFFERENTIATION INDUCTIVE AND USAGE THEREOF | |
| KR100827252B1 (en) | Hair reproducing stimulant using autologous hair follicular cells and composition thereof | |
| KR102583168B1 (en) | Media composition for growing dermal papilla cells comprising rotenone and albumin as active ingredients | |
| JP5993299B2 (en) | Melanocyte differentiation induction promoter and method of using the same |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A201 | Request for examination | ||
| E902 | Notification of reason for refusal | ||
| E701 | Decision to grant or registration of patent right | ||
| GRNT | Written decision to grant |